Piedmont Investment Advisors LLC cut its position in shares of Opko Health Inc. (NASDAQ:OPK) by 30.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 160,815 shares of the biotechnology company’s stock after selling 69,828 shares during the period. Piedmont Investment Advisors LLC’s holdings in Opko Health were worth $1,103,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System boosted its position in Opko Health by 7.5% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 400,278 shares of the biotechnology company’s stock valued at $2,634,000 after buying an additional 27,940 shares during the period. Intrinsic Edge Capital Management LLC purchased a new stake in Opko Health in the 2nd quarter valued at about $658,000. Alps Advisors Inc. boosted its position in Opko Health by 9.1% in the 3rd quarter. Alps Advisors Inc. now owns 550,909 shares of the biotechnology company’s stock valued at $3,779,000 after buying an additional 45,985 shares during the period. Balyasny Asset Management LLC boosted its position in Opko Health by 78.7% in the 2nd quarter. Balyasny Asset Management LLC now owns 40,262 shares of the biotechnology company’s stock valued at $265,000 after buying an additional 17,728 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. boosted its position in Opko Health by 611.8% in the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 1,445,310 shares of the biotechnology company’s stock valued at $9,913,000 after buying an additional 1,242,272 shares during the period. 22.91% of the stock is owned by institutional investors.
Shares of Opko Health Inc. (NASDAQ:OPK) opened at $4.98 on Friday. Opko Health Inc. has a twelve month low of $4.50 and a twelve month high of $12.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.48 and a current ratio of 1.66.
Several equities research analysts have issued reports on OPK shares. Cantor Fitzgerald set a $20.00 price objective on shares of Opko Health and gave the company a “buy” rating in a research report on Wednesday, October 25th. Zacks Investment Research raised shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. BidaskClub cut shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 11th. J P Morgan Chase & Co cut shares of Opko Health from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $12.00 to $7.00 in a research report on Thursday, September 14th. Finally, Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $16.00 price objective on shares of Opko Health in a research report on Monday, September 25th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. Opko Health presently has an average rating of “Buy” and a consensus price target of $13.97.
In other news, CEO Phillip Md Et Al Frost acquired 15,000 shares of Opko Health stock in a transaction that occurred on Tuesday, September 19th. The stock was purchased at an average price of $6.01 per share, for a total transaction of $90,150.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $18,444,395.51. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Opko Health, Inc. acquired 655,738 shares of Opko Health stock in a transaction that occurred on Monday, October 30th. The shares were purchased at an average price of $3.05 per share, with a total value of $2,000,000.90. Following the purchase, the insider now owns 6,678,752 shares in the company, valued at $20,370,193.60. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 710,738 shares of company stock valued at $2,330,151. Company insiders own 40.19% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Opko Health Inc. (OPK) Position Lowered by Piedmont Investment Advisors LLC” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://sportsperspectives.com/2017/12/16/opko-health-inc-opk-position-lowered-by-piedmont-investment-advisors-llc.html.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.